Celltrion announces positive results from the preclinical trials of COVID-19 antibody.

Early May, Korea based Celltrion announced that they have received positive results from their COVID-19 antibody pre-clinical trials.

With the ever-growing number of COVID-19 cases every day, pharmaceutical companies all over the world are scrambling to find treatment against this race against the novel virus. Experts are looking into options of using antibody treatment.

Recently a Korea based company Celltrion has published positive results from their antibody treatment for COVID-19. According to the authors, the antibody treatment can be 100 fold more effective in reducing the COVI-19 viral load in humans.

Early April, Celltrion announced that they are partnering with the Korean Center for disease control and have started a screening process to find an antibody against coronavirus. The study revealed that out of 300 candidates, bboaut 38 antibodies were potent and 14 were found to be strong neutralizing antibodies.

As the next step, the company created a cell line to mass-produce the antibodies. The cell line involves the production of cells continuously in an effort to consistently produce a certain amount of antibodies.

For a while now, several scientists around the world are testing antibody treatment on COVID-19. Most of these antibodies are extracted from people recovered from the said virus. Cellitron reported that their results showed an improvement in lung lesions and a reduction in clinical symptoms. By the end of the treatment, a significant relief was observed in the model organisms.

In a recent press release, Celltrion confirmed that they will be starting their clinical trials in July and will soon begin mass production. 

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Source

#Featured